Very Short Dual Antiplatelet Therapy after Drug-eluting Stent Implantation in Patients with High Bleeding Risk: Insight from the STOPDAPT-2 Trial.

Optimal antithrombotic therapy after percutaneous coronary interventions in high bleeding risk (HBR) patients is an important issue under active discussion. However, no previous study has compared different dual antiplatelet therapy (DAPT) duration in HBR patients. Recently, we have reported the STOPDAPT-2 (Short and optimal duration of dual antiplatelet therapy after everolimus-eluting cobalt-chromium stent) trial, suggesting the benefit of 1-month DAPT over 12-month DAPT with reduction of bleeding events without increase in cardiovascular events in an all-comer population. Very short DAPT might be beneficial particularly in HBR patients, and therefore, we conducted a post-hoc subgroup analysis based on the recently proposed ARC (academic research consortium) HBR criteria.